Abstract | OBJECTIVE: METHODS: Twelve women with metastatic gestational choriocarcinoma received 64 treatment cycles. All met the National Cancer Institute criteria for high-risk gestational trophoblastic tumors. Response was evaluated by monitoring serial serum beta-hCG levels. Toxicity was recorded using standard World Health Organization criteria. RESULTS: CONCLUSIONS:
|
Authors | J C Schink, D K Singh, A W Rademaker, D S Miller, J R Lurain |
Journal | Obstetrics and gynecology
(Obstet Gynecol)
Vol. 80
Issue 5
Pg. 817-20
(Nov 1992)
ISSN: 0029-7844 [Print] United States |
PMID | 1328977
(Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Dactinomycin
- Vincristine
- Etoposide
- Cyclophosphamide
- Methotrexate
|
Topics |
- Adult
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Cyclophosphamide
(administration & dosage)
- Dactinomycin
(administration & dosage)
- Etoposide
(administration & dosage)
- Female
- Follow-Up Studies
- Humans
- Methotrexate
(administration & dosage)
- Pregnancy
- Prospective Studies
- Risk Factors
- Trophoblastic Neoplasms
(drug therapy, secondary)
- Uterine Neoplasms
(drug therapy, pathology)
- Vincristine
(administration & dosage)
|